Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/174—Vitamins
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K40/00—Shaping or working-up of animal feeding-stuffs
  • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/15—Vitamins
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
  • A23P20/10—Coating with edible coatings, e.g. with oils or fats
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
  • A23P20/10—Coating with edible coatings, e.g. with oils or fats
  • A23P20/105—Coating with compositions containing vegetable or microbial fermentation gums, e.g. cellulose or derivatives; Coating with edible polymers, e.g. polyvinyalcohol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/11—Encapsulated compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/673—Vitamin B group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2813—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4833—Encapsulating processes; Filling of capsules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5089—Processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
  • B01J13/02—Making microcapsules or microballoons
  • B01J13/06—Making microcapsules or microballoons by phase separation
  • B01J13/14—Polymerisation; cross-linking
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2250/00—Food ingredients
  • A23V2250/70—Vitamins
  • A23V2250/704—Vitamin B
  • A23V2250/7044—Vitamin B2

Definitions

• the present invention relates to a new delivery system of water-soluble vitamins (i.e. B vitamins (especially B2)) for the large intestine.
• B vitamins especially B2
• These nutritional ingredients are useful for gut and metabolic health in monogastric animals (such as swine and poultry as well as fish), especially in humans.
• Riboflavin (vitamin B2)
• Faecalibacterium prausnitzii which is a marker species for a healthy gut.
• EP2914135 describes use of riboflavin for the selective stimulation of F. Prausnitzii.
• very high dosages of riboflavin are required, because the main part is already destroyed or absorbed before reaching the large intestine. Release in the small or large intestine is usually achieved with controlled release capsules or tablets.
• the active substances are incorporated in a capsule or tablet that is coated with one or more coatings that lead to controlled release.
• tablets and capsules as delivery system have several drawbacks.
• the amount of active that can be incorporated in a single tablet or capsule limited by the available volume. Especially very young and elderly patients have difficulties with swallowing tablets or capsules. Residence time of capsules and tablets in the stomach is very variable and release is very punctual, which may lead to very high local concentrations of the active, which may cause detrimental effects.
• Multiparticulate forms like powders, granules, beadlets or pellets overcome these drawbacks.
• application of controlled release coatings on multiparticulate dosage forms is difficult due to the larger specific surfaces as compared to tablets or capsules.
• the required amount of coating material is much higher than for tablets or capsules, reducing the available space for payload.
• Suitable coating materials for release in the small intestine often comprise pH sensitive polymers. This approach utilizes the existence of the pH gradient in the GIT that increases progressively from the stomach (pH 1.5-3.5) and small intestine (pH 5.5-6.8) to the large intestine (6.4-7.0).
• the most commonly used pH-dependent polymers are derivatives of acrylic acid and cellulose.
• Various pH-dependent coating polymers include cellulose acetate phthalate (CAP) (Aquateric ® ), poly vinyl acetate phthalate(PVAP) (Coateric ® ), hydrox- ypropyl methyl cellulose phthalate(HPMCP), and methacrylic acid copolymers, commonly known as methacrylate copolymers or Eudragit.
• pH sensitive coating technique An important limitation of the pH sensitive coating technique is the uncertainty of the location and environment in which the coating may start to dissolve. It is possible that enteric coating alone may lead to premature drug release in the small intestine due to a variation in Gl motility.
• Gl microflora as a mechanism of drug release in the colonic region has been of great interest to researchers in the past.
• the majority of bacteria are present in the distal gut although they are distributed throughout the Gl tract.
• the colonic bacteria are predominately anaerobic in nature and secrete enzymes that are capable of metabolizing both endogenous and exogenous substrates such as carbohydrates and proteins that escape digestion in the upper Gl tract.
• Polysaccharides naturally occurring in plant e.g., pectin,
• guar gum, inulin), animal (e.g., chitosan, chondroitin sulfate), algal (e.g., alginates), or microbial (e.g., dextran) origins were studied for colon targeting. These are broken down by the colonic microflora to simple saccharides by saccharolytic species like bacteroides and bifidobacteria. [Jose, S., K. Dhanya, T. A. Cinu, J. Litty and A. J. Chacko (2009). "Colon targeted drug delivery: different approaches.” J. Young Pharm. 1 (1 ): 13-19.].
• Fermentable biopolymers have been used as encapsulating matrix.
• matrix encapsulation the active substance is homogenously distributed in a protective matrix, in this case a fermentable biopolymer.
• matrix encapsulation has several serious drawbacks. Due to the high viscosity of the biopolymers, the matrix solution, e.g. in a spray drying or gel encapsulation is very dilute, making it difficult and expensive to dry. Payload in matrix encapsulation is relatively low (typically less than 50%).
• the goal of the present invention was to find an improved multiparticulate delivery system (formulation) to improve the stability of water-soluble vitamins (i.e. B vitamins (especially B2)) during the transport through the stomach and the small intestine (before be- ing released in the large intestine) so that the availability and the efficacy of water-soluble vitamins (i.e. B vitamins (especially B2)) are improved.
• B vitamins especially B2
• the new delivery system should be producible in a simple and industrial applicable way.
• the delivery system has improved properties. Furthermore, the delivery system can be produced in batch-wise as well as in by continuous process.
• the new delivery system (DS) according to the present invention consists of
• a solid core which comprises at least one water-soluble vitamin (especially vitamin B2), and
• the active substance, which is in the core is a water-soluble vitamin, especially a B vitamin, more preferred it is vitamin B2.
• Nutraceuticals are compounds that provide health benefits in the animal.
• Preferred nutraceuticals in the present invention are organic acids, omega 3 fatty acids, omega 6 fatty acids, omega 8 fatty acids, long chain fatty acids, polyphenols (such as resveratrol or genistein), prebiotics, probiotics, essential oils, and antimicrobial peptides.
• the present invention relates to a delivery system (DS1 ), which is the delivery system (DS), wherein the solid core comprises at least one nutraceutical is chosen from the group consisting of organic acids, omega 3 fatty acids, omega 6 fatty acids, omega 8 fatty acids, long chain fatty acids, polyphenols (such as resveratrol or genistein), prebiotics, probiotics, essential oils, and antimicrobial peptides.
• nutraceutical is chosen from the group consisting of organic acids, omega 3 fatty acids, omega 6 fatty acids, omega 8 fatty acids, long chain fatty acids, polyphenols (such as resveratrol or genistein), prebiotics, probiotics, essential oils, and antimicrobial peptides.
• Preferred organic acids are short chain fatty acids (SCFAs) as well as their salts.
• Short-chain fatty acids are fatty acids with two to six carbon atoms.
• SCFAs are the following: formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid and salts of these acids. Especially preferred is propionic acid and salts thereof.
• the most preferred water-soluble vitamin in the context of the present invention is vitamin B2 (Riboflavin).
• the present invention relates to a delivery system (DS2), which is the delivery system (DS) or (DS1 ), wherein the water-soluble is vitamin B2.
• another embodiment of the present invention is related to a delivery system, which only comprises vitamin B2 as an active ingredient (nutraceutical).
• the delivery system (solid core and coatings) is free of any other nutraceutical chosen from the group consisting of organic acids, omega 3 fatty acids, omega 6 fatty acids, omega 8 fatty acids, long chain fatty acids, polyphenols (such as resveratrol or genistein), prebiotics, probiotics, essential oils, and antimicrobial peptides.
• the present invention relates to a delivery system (DS3), which is the delivery system (DS), (DS1 ) or (DS2), wherein the delivery system (solid core and coatings) is free of any other nutraceutical chosen from the group consisting of organic acids, omega 3 fatty acids, omega 6 fatty acids, omega 8 fatty acids, long chain fatty acids, polyphenols (such as resveratrol or genistein), prebiotics, probiotics, essential oils, and antimicrobial peptides.
• DS3 is the delivery system (DS), (DS1 ) or (DS2)
• the delivery system solid core and coatings
• any other nutraceutical chosen from the group consisting of organic acids, omega 3 fatty acids, omega 6 fatty acids, omega 8 fatty acids, long chain fatty acids, polyphenols (such as resveratrol or genistein), prebiotics, probiotics, essential oils, and antimicrobial peptides.
• the delivery system according to the present invention comprises an inner coating, which needs to fulfill the criteria as defined.
• Suitable materials for the inner coating are for example alginate, chitosan, pectin, cyclodextrin as well as other gums.
• Preferred coating materials for the inner coating are alginate or pectin.
• the inner coating is crosslinked. This can be done by commonly known crosslinking compounds. In case alginate is used that can be done by Mg and/or Ca ion (by the use of a salt).
• the crosslinker can be spray onto to solid core after having applied the inner coating or simultaneously. Or the coated particles can be dipped into a solution comprising the crosslinker.
• crosslinker is sprayed onto the particles after having applies the inner coating layer.
• Another advantage of the present invention also lies therein that the production of the new delivery system according to the present invention can be done batch-wise as well as continuously. In contrast to the systems known from the prior art this is a huge advantage also in view of the industrial production of such product. The details of the process are disclosed below.
• the present invention relates to a delivery system (DS4), which is the delivery system (DS), (DS1 ), (DS2) or (DS3), wherein the material of the inner coating is chosen from group consisting of alginate, chitosan, pectin, cyclodextrin as well as other gums.
• the present invention relates to a delivery system (DS4'), which is the delivery system (DS4), wherein the material of the inner coating is alginate or pectin.
• the inner coating layer is covering the core (more or less) completely.
• the (layer of the inner coating has (more or less) the same thickness when applied on the solid core.
• the thickness of the inner coating layer is at least 5 ⁇ and not more than 20 ⁇ " ⁇ .
• the thickness of the inner coating layer is between 5 ⁇ - ⁇ ⁇ .
• the present invention relates to a delivery system (DS5), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4) or (DS4'), wherein the thickness of the inner coating layer is 5 ⁇ - 10 ⁇ .
• the inner coating layer is crosslinked with at least one crosslinking agent. Any suitable crosslinker can be used. Very suitable (and therefore preferred are Mg and Ca ions (they are added in form of a salt).
• the present invention relates to a delivery system (DS6), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4') or (DS5), wherein the inner coating layer is crosslinked with at least one crosslinking agent (preferably with Mg and/or Ca ions).
• DS6 is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4') or (DS5), wherein the inner coating layer is crosslinked with at least one crosslinking agent (preferably with Mg and/or Ca ions).
• the present invention relates to a delivery system (DS7), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4'), (DS5) or (DS6), wherein the crosslinked inner coating layer is Na alginate or Na pectin.
• DS7 is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4'), (DS5) or (DS6), wherein the crosslinked inner coating layer is Na alginate or Na pectin.
• the delivery system according to the present invention comprises an outer coating, which needs to fulfill the criteria as defined.
• Suitable materials which fulfill the criteria for the outer coating is for example shellac, methacrylate copolymers and fats.
• the present invention relates to a delivery system (DS8), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4'), (DS5), (DS6) or (DS7), wherein the material of the outer coating is chosen from group consisting of shellac, methacrylate copolymers and fats.
• the outer coating layer is covering the inner coating (more or less) completely. Ideally the layer of the outer coating has (more or less) the same thickness when applied on the inner coating.
• the thickness of the outer layer is at least 10 ⁇ and usually less than 30 ⁇ .
• the thickness of the outer coating layer is between 10 and 20 ⁇ " ⁇ .
• the present invention relates to a delivery system (DS9), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4'), (DS5), (DS6), (DS7) or (DS8), wherein the thickness of the outer coating layer is 10 ⁇ - 20 ⁇ " ⁇ .
• the solid core of the delivery system according to the present invention is usually 10 - 85 wt- %, preferably 50 - 75 wt-%, based on the total weight of the delivery system.
• the present invention relates to a delivery system (DS10), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4'), (DS5), (DS6), (DS7), (DS8) or (DS9), wherein the solid core of the delivery system is 10 - 85 wt- %, preferably 50 - 75 wt-%, based on the total weight of the delivery system.
• DS10 is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4'), (DS5), (DS6), (DS7), (DS8) or (DS9)
• the solid core of the delivery system is 10 - 85 wt- %, preferably 50 - 75 wt-%, based on the total weight of the delivery system.
• the inner coating of the delivery system according to the present invention is usually 1 - 20 wt- %, preferably 1 - 10 wt-%, based on the total weight of the delivery system.
• the present invention relates to a delivery system (DS1 1 ), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS4), (DS4'), (DS5), (DS6), (DS7), (DS8), (DS9) or (DS10), wherein the inner coating of the delivery system is 10 - 85 wt- %, preferably 1 - 10 wt-%, based on the total weight of the delivery system.
• the outer coating of the delivery system according to the present invention is usually 1 - 30 wt- %, preferably 15 - 30 wt-%, based on the total weight of the delivery system. Therefore, the present invention relates to a delivery system (DS12), which is the delivery system (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10) or (DS1 1 ), wherein the outer coating of the delivery system is 1 - 30 wt- %, preferably 15 - 30 wt-%, based on the total weight of the delivery system
• the delivery system according to the present invention can be up to 2mm in size.
• the size is defined by the longest diameter of the particle.
• the shape of the particle is not an es- sential feature of the present invention. Also the size distribution of the particles is no essential.
• the size and the shape of the particle is mainly defined by the solid core of the delivery system. Depending on the use of the delivery system the size can be adjusted.
• the delivery system according to the present invention is produced by commonly known technology.
• the solid core is produced in a first step and then the inner and outer coatings are applied.
• the new delivery system can be produced batch-wise of continuously.
• the new particles can be produce as follows:
• first step the solid core is produced by spray drying process, then in a second step the solid cores (obtained in the first step) are coated by spray coating with the coating material of the inner coating, and then the crosslinker is spray onto the particle. In a third step the outer coating is spray onto the particle obtained by the previous steps and finally the particles are dried.
• Another option how to produce the new delivery system is a continuous process, wherein the solid cores are produced first and then the coating steps are done spray onto the particle one after the other. These processes are ideal to apply in an industrial scale.
• the present invention also related to a process of production (P) of any of the particles (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10), (DS1 1 ) or (DS12), wherein the process is carried out batch-wise.
• the present invention also related to a process of production (P1 ) of any of the particles (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10), (DS1 1 ) or (DS12), wherein the process is carried out continuously.
• the new delivery systems (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10), (DS1 1 ) and/or (DS12) according to the present invention can be used as such or incorporated into application forms.
• the new delivery systems (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10), (DS1 1 ) and/or (DS12) can used as such in any dietary supplement, food product, feed product, personal care product or pharmaceutical product.
• the new delivery systems (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10), (DS1 1 ) and/or (DS12) can also be part of a premix formulation, which can then be used to formulate any dietary supplement, food product, feed product, personal care product or pharmaceutical product.
• the invention also relates to a process for the production of a premix, dietary supplement, food product, feed product, personal care product or pharmaceutical product using at least one delivery system (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10), (DS1 1 ) or (DS12).
• DS delivery system
• the invention also relates to a premix, dietary supplement, food product, feed product, personal care product or pharmaceutical product comprising at least one delivery system (DS), (DS1 ), (DS2), (DS3), (DS3'), (DS3"), (DS4), (DS5), (DS5'), (DS6), (DS7), (DS8), (DS9), (DS10), (DS1 1 ) or (DS12).
• DS delivery system
• aqueous shellac preparation with a solids content of 25% (Aquagold SSB, Stroever) was sprayed as outer coating. After spraying of the shellac, the product was dried in the fluid bed. 103g coated granules were obtained.
• Composition of the final coated granulate was 60% Riboflavin, 9% alginate, 1 % Ca chloride and 30% shellac.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Polymers & Plastics (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Food Science & Technology (AREA)
• Birds (AREA)
• Mycology (AREA)
• Nutrition Science (AREA)
• Organic Chemistry (AREA)
• Zoology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dispersion Chemistry (AREA)
• Animal Husbandry (AREA)
• Biotechnology (AREA)
• Inorganic Chemistry (AREA)
• Dermatology (AREA)
• Medicinal Preparation (AREA)
• Fodder In General (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• General Preparation And Processing Of Foods (AREA)
• Manufacturing Of Micro-Capsules (AREA)
• Emergency Medicine (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=60473269

Family Applications (2)

Family Applications After (1)

Country Status (7)

Cited By (3)

Families Citing this family (1)

Citations (2)

Family Cites Families (10)

• 2018
  • 2018-10-30 US US16/761,053 patent/US11872316B2/en active Active
  • 2018-10-30 CN CN201880071097.1A patent/CN111315236A/zh active Pending
  • 2018-10-30 US US16/761,096 patent/US11602503B2/en active Active
  • 2018-10-30 ES ES18795592T patent/ES3035248T3/es active Active
  • 2018-10-30 EP EP18795592.7A patent/EP3703514B1/en active Active
  • 2018-10-30 JP JP2020518607A patent/JP7331323B2/ja active Active
  • 2018-10-30 KR KR1020207014379A patent/KR102790073B1/ko active Active
  • 2018-10-30 KR KR1020257004027A patent/KR20250025501A/ko active Pending
  • 2018-10-30 KR KR1020207014377A patent/KR102790067B1/ko active Active
  • 2018-10-30 KR KR1020257004033A patent/KR20250025502A/ko active Pending
  • 2018-10-30 ES ES18795593T patent/ES3034026T3/es active Active
  • 2018-10-30 EP EP18795593.5A patent/EP3703515B1/en active Active
  • 2018-10-30 WO PCT/EP2018/079662 patent/WO2019086425A1/en not_active Ceased
  • 2018-10-30 JP JP2020518603A patent/JP7331322B2/ja active Active
  • 2018-10-30 WO PCT/EP2018/079665 patent/WO2019086427A1/en not_active Ceased
  • 2018-10-30 CN CN201880071125.XA patent/CN111315237A/zh active Pending

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events